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Abstract
Recent publications have moved us significantly closer to a complete understanding of the mammalian
target of rapamycin (mTOR) signaling pathway, which plays a central role in the control of growth
and metabolism and is dysregulated in a broad spectrum of human diseases, including cancer,
tuberous sclerosis, diabetes, and cardiovascular and neurodegenerative diseases. Rapamycin-related
mTOR inhibitors have shown clinical efficacy in several of these diseases, and novel inhibitors
currently in development will be valuable tools for further dissections of the mTOR signaling network
in human health and disease.
Introduction and context
Nearly 15 years have passed since the discovery of
mammalian target of rapamycin (mTOR) as the protein
kinase whose signaling functions are modulated by the
natural product rapamycin [1-3]. The mTOR mRNA
transcript encodes a relatively large (~300 kDa) poly-
peptide with an extended amino-terminal domain and a
carboxy-terminal kinase domain that bears considerable
sequence similarity to the catalytic domains of the
phosphoinositide-3-kinases (PI3Ks) [4]. In spite of the
similarity to lipid kinases, the mTOR kinase domain
phosphorylates protein substrates on serine or threonine
residues. Mammalian cells express several additional
mTOR-related kinases, which collectively comprise a
family of large signaling proteins named the PI3K-related
kinases [4,5].
Studies of mTOR signaling functions have been immea-
surably facilitated by the availability of the natural
product rapamycin, a potent and highly selective
inhibitor of a subset of mTOR signaling functions. As a
chemical probe, rapamycin enabled the identification of
the mTOR polypeptide, the cloning of its cognate cDNA,
and numeous fundamental insights into the physiologic
and pathologic roles of mTOR in a broad array of cells,
tissues, and organ systems. Rapamycin also possesses
established clinical utility as an immunosuppressant/
anti-inflammatory agent in organ transplantation and
coronary arterial diseases [6,7]. More recently, rapamy-
cin-related mTOR inhibitors (collectively termed 'rapa-
logs') have shown activity in patients with renal cancer
and other malignant diseases, and many drug companies
are aggressively developing second-generation mTOR
inhibitors with the hope that these compounds will
show broader efficacy and an improved safety profile
relative to the rapalogs. These new mTOR inhibitors, like
rapamycin, will undoubtedly serve as valuable chemical
probes for more detailed dissections of mTOR signaling
in healthy and diseased cells.
Two mTOR-containing protein complexes are expressed
in mammalian cells (Figure 1). The mTOR complex
(mTORC)1 contains the 'signature' subunit, Raptor,
together with LST8 and PRAS40, and the activity of this
multi-subunit complex is acutely sensitive to rapamycin
[1,8]. The salient function of mTORC1 is to coordinate
growth factor and nutrient availability with the transla-
tion of a subset of mRNAs into proteins needed for cell-
cycle progression and mitotic cell division [2,9].
mTORC2 bears a distinct subunit composition, with
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LST8 and Protor as additional components [1,8]. It plays
a key role in the phosphorylation of AKT at Ser473,
which is located in the 'hydrophobic motif' of AKT and
other members of the protein kinase A, G, and C (AGC)
family [10,11]. Remarkably, mTORC2 is not directly
inhibited by rapamycin [12,13]; however, long-term
exposure to the drug disrupts the assembly of functional
mTORC2 [14,15]. Recent studies indicate that mTORC1
and mTORC2 are found in both the cytoplasm and the
nucleus; however, they show only partially overlapping
sub-compartmental localizations [15,16].
In mammalian cells, mTORC1 activity is stimulated by
growth factors and amino acids, and inhibited by
hypoxia and depletion of the main source of metabolic
energy, ATP (Figure 1). The mechanism through which
growth factors activate mTORC1 has been intensively
studied, and the PI3K-activated protein kinase AKT is
clearly a major player in the transmission of growth
factor-derived signals to mTOR. A nodal point of
convergence for mTORC1 regulatory signals delivered
by growth factors, hypoxia, and ATP is a heterodimeric
protein complex consisting of tuberous sclerosis com-
plex 1 (TSC1) and TSC2 subunits (hereafter termed
TSC1/2), which functions as a GTPase-activating protein
(GAP) for the Ras-related GTPase Rheb [17,18]. In its
active GTP-bound state, Rheb binds to and activates
mTORC1 [18]; hence, TSC1/2 acts as a suppressor of
mTORC1 activity by limiting the amount of GTP-bound
Rheb available to stimulate mTORC1. The signals that
converge on TSC1/2 largely target the TSC2 subunit, and
directly or indirectly modulate the Rheb-GAP activity of
TSC1/2. Given that protein synthesis and mitotic cell
division are extremely energy-dependent processes, it is
not surprising that mTORC1 activity is strongly influ-
enced by cellular bioenergetics. A key player in the
energy-sensing pathway upstream of mTORC1 is AMP-
dependent protein kinase (AMPK), which is activated by
an increase in the AMP to ATP ratio (a sensitive indicator
of intracellular energy depletion) [19]. AMPK phosphor-
ylates TSC2, thereby increasing the repressive effect of
TSC1/2 on Rheb-dependent mTORC1 signaling [20,21].
Collectively, this elegant regulatory network ensures that
mTORC1 activity is elevated when supplies of growth
factors and metabolic precursors are sufficient to support
cell growth and proliferation. Disruption of any of the
mechanisms responsible for repressing mTORC1 activity
(for example, impaired TSC1/2 function) leads to
persistent mTORC1 activation, and favors inappropriate
cell growth (hyperplasia) and proliferation.
Recent studies have addressed several major conceptual
gaps in our understanding of mTOR regulation and
function. These studies have forged new connections
between growth factor receptor- and metabolism-related
signals and mTORC1 activity. A second major area of
uncertainty surrounds mTORC2 regulation and activity,
Figure 1. Regulation of mammalian target of rapamycin (mTOR)
signaling functions
mTOR complex (mTORC)1 regulates protein synthesis in cycling cells by
promoting cap-dependent mRNA translation, and the assembly of actively
translating poly-ribosomes (polysomes). The signaling functions of mTORC1
are tightly controlled by growth factors, amino acids, and bioenergetic
molecules, including oxygen and ATP. Growth factor receptors commu-
nicate with mTORC1 by activating phosphoinositide-3-kinase (PI3K). A key
target for PI3K is the AGC family kinase AKT, which is phosphorylated at
Thr308 in the activation loop (AL) by PI3K-dependent kinase-1. Full
activation of AKT requires a second phosphorylation event at Ser473 in the
hydrophobic motif (HM), which is carried out by mTORC2. mTORC2 is
also responsible for a third phosphorylation event at Thr450 in the turn
motif (TM), which promotes AKT signaling by increasing the stability of this
protein kinase. The signaling functions of mTORC2 are stimulated by direct
binding to the tuberous sclerosis complex (TSC)1 and TSC2 heterodimer
(TSC1/2), and possibly by an undefined signal generated by PI3K. Once
activated, AKT phosphorylates TSC2, which inhibits TSC1/2-associated
GTPase-activating protein (GAP) activity, leading to increased levels of
mTORC1-activating, GTP-bound Rheb. Conversely, hypoxia and ATP
depletion (revealed by an increase in the AMP:ATP ratio) stimulate TSC1/2
GAP activity via induction of REDD1 (Regulated in Development and DNA
Damage Responses-1) and AMPK activities, respectively. Genotoxic stress-
induced p53 activity also stimulates TSC1/2 GAP activity via induction of
Sestrins, which bind to and stimulate AMPK. Finally, amino acids activate
mTORC1 by inducing the assembly of Rag heterodimers (e.g., the RagA-
RagC heterodimers shown in the figure). Deregulated mTORC1 activity
promotes the synthesis of proteins that drive inappropriate cell survival and
growth, and supports tumor progression. The inset box shows the newly
defined, Fbxw7-dependent mechanism that mediates mTOR ubiquitination
and subsequent proteasomal degradation. Loss of the tumor suppressor
Fbxw7 stabilizes mTOR and promotes elevated mTORC1 and mTORC2
activities in cancer cells.
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several recent investigations have underscored the
importance of mTOR pathway deregulation in cancer
development, and shed new light on mechanisms of
tumor resistance to mTOR inhibitor-based therapies.
Major recent advances
Our perception of the regulatory controls that govern
mTORC1 activity continues to evolve. As described
above, growth factors are known to signal to mTORC1
via PI3K-AKT-dependent repression of TSC1/2. A recent
report indicates that mTORC1 also responds to mito-
genic signals delivered through the Ras pathway [22].
The authors demonstrate that the Ras-activated, extra-
cellular signal-regulated kinase (ERK) phosphorylates
TSC2, thereby dampening the repressive effect of TSC1/2
on Rheb-mTORC1 activity [22]. These studies also
implicate mTORC1 deregulation in Ras-dependent
oncogenesis in humans. Our view of the influence of
cellular bioenergetics on mTORC1 activity was enhanced
with the discovery that AMPK directly modulates
mTORC1 through phosphorylation of Raptor [21].
Finally, a particularly noteworthy advance during the
past year involved the identification of a family of small
GTP-binding proteins as key players in the transmission
of amino acid-derived stimulatory signals to mTORC1
[23,24]. Mammalian cells express four Rag GTPases
(RagA-D), which form hetero-oligomeric complexes in
response to unidentified, amino acid-derived signals.
These active Rag hetero-oligomers bind to mTORC1 via
Raptor, and stimulate both the redistribution of
mTORC1 to a different cytoplasmic sub-compartment,
and an increase in mTORC1-associated kinase activity.
Several recent reports have also provided important
insights into the regulation and functions of mTORC2.
Remarkably, TSC1/2, which functions as a repressor of
mTORC1 activity, was identified as a positive regulator
of mTORC2 activity [25]. The stimulatory effect of TSC1/
2 on mTORC2 is independent of its Rheb-GAP activity;
instead, TSC1/2 interacts directly with mTORC2, and
activates the complex through an allosteric mechanism.
Two reports indicate that mTORC2 exerts a broader than
previously appreciated influence on AKT and certain
other AGC family protein kinases [26,27]. In addition to
its well-characterized functions as an effector of Ser473
phosphorylation in the hydrophobic motif of AKT,
mTORC2 phosphorylates conserved threonine residues
located in the 'turn motifs' of AKT and the a, b, g,a n de
isoforms of protein kinase C. Surprisingly, turn motif
phosphorylation serves a constitutive, 'housekeeping'
function that is required to maintain steady-state
expression levels of these particular AGC kinase family
members. Interestingly, loss of mTORC2 function leads
to reduced AKT expression, and renders the remaining
AKT molecules more highly dependent on the molecular
chaperone, HSP90, for protection from proteasomal
degradation [27].
New mechanisms of mTOR pathway deregulation
during the evolution of cancer cells continue to be
elucidated. Two reports demonstrated that Rheb over-
expression supports the development of more aggressive
B-cell lymphomas, as well as the survival of dormant
epithelial tumor cells [28,29]. Conversely, tumor devel-
opment is suppressed by a newly described, p53-
dependent mechanism involving Sestrin-1 and Sestrin-2.
These proteins bind to and activate AMPK, which
promotes TSC1/2-dependent inhibition of Rheb and
mTORC1 [30]. Yet another avenue whereby tumor cells
acquire mTOR pathway deregulation was unveiled with
the discovery that the F-box protein Fbxw7 targets the
mTOR polypeptide for ubiquitination and subsequent
degradation by the proteasome. Fbxw7 represents the
targetingsubunitofanSCF-typeubiquitinE3ligase,andis
a known tumor suppressor that counts cyclin E and c-Myc
among its other known substrates [31]. Loss of Fbxw7
duringtumorigenesis leadstoelevated steady-stateexpres-
sion of mTOR and enhanced mTOR signaling. Interest-
ingly, Fbxw7-deficient cancer cells are sensitive to mTOR
inhibitors, suggesting that Fbxw7 might be a useful
biomarker for therapeutic responsiveness to these drugs
in cancer patients.
Future directions
The drive to fully understand the signaling network that
surrounds the two mTOR complexes has intensified with
the entry of first-generation mTOR inhibitors into the
oncology clinics. From the translational perspective, we
urgently need to understand whether the new, second-
generation mTOR kinase inhibitors, which target both
mTORC1 and mTORC2 [1], will have a clear therapeutic
advantage over the mTORC1-selective rapamycin ana-
logs already in the clinic. We predict that additional
genetic alterations leading to deregulated signaling
through mTORC1 and/or mTORC2 will be uncovered
in human cancers, and that these impending insights will
enable clinicians to predict which cancer patients are
most likely to respond favorably to mTOR inhibitor-
based therapeutic regimens. On a more basic level, we
eagerly await the results of ongoing studies that build on
the new knowledge that Rag GTPases relay amino acid-
derived signals to mTORC1. Finally, clinical experience
with mTOR inhibitors in cancer patients will undoubt-
edly raise new questions to be addressed by the basic
research laboratories. From the bench to the bedside and
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undoubtedly hold the interest of biologists and clin-
icians alike, for a long time to come.
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